Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

½ÃÇèÁÖÀÔÀ» ÀÌ¿ëÇÑ Á¶¿µÁõ°­ 3Â÷¿ø ÃÊ°í¼Ó Æó ÀÚ±â°ø¸íÇ÷°ü Á¶¿µ¼úÀÇ Æò°¡ : ´ÜÀÏ¿ë·® ¹× ÀÌÁß¿ë·®ÀÇ ºñ±³ Assessment of Contrast-enhanced 3D Ultrafast Pulmonary MR Angiography Using Test Injection : Comparison between Single Dose and Double Dose

´ëÇѹæ»ç¼±ÀÇÇÐȸÁö 1999³â 41±Ç 1È£ p.73 ~ 78
¼Ò¼Ó »ó¼¼Á¤º¸
±è¸í±Ô/Myung Gyu Kim ¿ÀÀ¯È¯/½Å±ÔÈñ/Á¤±Ôº´/¼­¿øÇõ/Yu Whan Oh/Kue Hee Shin/Kyoo Byung Chung/Won Hyuck Suh

Abstract

¸ñÀû : Á¶¿µÁõ°­ 3Â÷¿ø ÃÊ°í¼Ó ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼úÀº ÃÖ±Ù °æµ¿¸Æ, ´ëµ¿¸Æ, ½Åµ¿¸Æ, Àå°£µ¿¸Æ
¹× ¹®Á¤¸Æ µîÀ» Æ÷ÇÔÇÏ´Â Ç÷°üµéÀÇ °Ë»ç·Î ³Î¸® ÀÌ¿ëµÇ°í ÀÖ´Ù. ½Ã°£°áÁ¤°Ë»ç¸¦ ÀÌ¿ëÇÏ¿©
¿µ»óȹµæ½Ã°£À» °áÁ¤ÇÑ ÈÄ Á¶¿µÁõ°­ 3Â÷¿ø ÃÊ°í¼Ó Æó ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼úÀ» Á¶¿µÁ¦¾çÀ» ´Ü
ÀÏ¿ë·® ¹× ÀÌÁß¿ë·®À¸·Î º¯È­½ÃÄÑ ¾òÀº ÈÄ ÀÌ ¿µ»óÀ» Æò°¡ÇÏ°íÀÚ ÇÑ´Ù.
´ë»ó ¹× ¹æ¹ý : °¡µ¹¸®´½Á¶¿µÁõ°­ ÃÊ°í¼Ó Æó ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼ú(3D FISP, TR¡²msec¡³
/TE¡²msec¡³=5.0/2.0, 25¡Æ¼÷ÀÓ°¢)À» 20¸íÀÇ Á¤»ó ¼ºÀÎ ÀÚ¿øÀÚ¿¡¼­ ½ÃÇàÇÏ¿´´Ù. ÀÓÀÇ·Î 2
±ºÀ¸·Î ³ª´« ÈÄ ÇÑ ±ºÀº 0.1 mmol/§¸(´ÜÀÏ¿ë·®ÁÖÀÔ±º).´Ù¸¥ ±ºÀº 0.2mmol/§¸( ÀÌÁß¿ë·®ÁÖÀÔ
±º)ÀÇ Á¶¿µÁ¦¸¦ ÁÖÀÔÇÑ ÈÄ Æó ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼úÀ» ½ÃÇàÇÏ¿´´Ù. Àü ¿¹¿¡¼­ ½Ã°£°áÁ¤°Ë»ç
¸¦ 1 ³»Áö 2§¢ÀÇ Á¶¿µÁ¦¸¦ ÀÌ¿ëÇÏ¿© ÁÖÀÔÇÑ ÈÄ È¾´Ü¸é
turbo-FLASH(TR/TE/TI=8.5/4.0/100, 10¡Æ¼÷ÀÓ°¢)¸¦ ÀÌ¿ëÇÏ¿© ½ÃÇàÇÏ¿´´Ù. µÎ ±º¿¡¼­ ¾òÀº
¿µ»óµéÀ» Àüü ¿µ»óÈ­Áú°ú Æ󵿸ƽð¢È­¸¦ Æò°¡ÇÏ´Â Á¤¼ºÀû ºÐ¼®¹æ¹ý°ú Ç÷°üÀÇ ´ëÁ¶µµ´ëÀâ
À½ºñ¸¦ ÃøÁ¤ÇÑ Á¤·®Àû ºÐ¼®¹æ¹ýÀ» ÀÌ¿ëÇÏ¿© ºÐ¼®ÇÏ¿´´Ù.
°á°ú : Á¶¿µÁ¦ ¾çÀ» ´Þ¸®ÇÑ µÎ ±ºÀÇ Àüü ¿µ»óÈ­ÁúÀÇ Â÷ÀÌ¿¡¼­´Â Åë°èÀû Àǹ̰¡ ¾ø¾ú´Ù
(P>0.05). Æ󵿸ƽð¢È­¸¦ Æò°¡ÇÑ °á°ú´Â µÎ ±º¿¡¼­ Á߽ɵ¿¸Æ°ú ´ë¿±µ¿¸ÆÀº ¸ðµÎ ¿ì¼öÇÏ°Ô
Àß º¸¿´´Ù. ºÐÀýµ¿¸ÆÀÇ ½Ã°¢¼º Á¡¼ö´Â ´ÜÀÏ¿ë·®À» »ç¿ëÇÑ °æ¿ì 2.83¡¾0.32, ÀÌÁß¿ë·®À» »ç¿ë
ÇÑ °æ¿ì 2.85¡¾0.3À¸·Î µÎ ±º°£ÀÇ Åë°èÀû Àǹ̴ ¾ø¾ú´Ù(P>0.05). °¢ Á߽ɵ¿¸Æ, ´ë¿±µ¿¸Æ, ºÐ
Àýµ¿¸ÆÀÇ ´ëÁ¶µµ´ëÀâÀ½ºñÀÇ Â÷ÀÌ´Â Åë°èÀûÀ¸·Î ÀǹÌÀÖ°Ô ÀÌÁß¿ë·®À» »ç¿ëÇÑ ±º¿¡¼­ ³ô¾Ò
´Ù.(P>0.05).
°á·Ð : Æ󵿸ÆÀÇ ´ëÁ¶µµ´ëÀâÀ½ºñÀÇ Â÷ÀÌ´Â Åë°èÀûÀ¸·Î ÀǹÌÀÖ°Ô ÀÌÁß¿ë·®À» »ç¿ëÇÑ ±º¿¡¼­
³ô¾ÒÀ¸³ª Àüü¿µ»óÈ­Áú ¹× Æ󵿸ƽð¢È­ÀÇ Â÷ÀÌ´Â Àǹ̰¡ ¾ø¾î Á¶¿µÁ¦ ¾çÀ» ´ÜÀÏ¿ë·®À¸·Î
³·Ãâ ¼ö ÀÖ´Â °¡´É¼ºÀ» Á¦½ÃÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : Contrast-enhanced 3-D ultrafast MR angiography is a widely accepted MR
imaging technique for the evaluation of the carotid artery, aorta, renal artery, mesenteric
artery and portal venous system. To estimate its clinical usefulness, single-and
double-dose contrast-enhanced 3-D ultrafast pulmonary MR angiography was assessed
after a timing examination was performed.
Materials and Methods : Twenty volunteers underwent gadolinium-enhanced ultrafast
pulmonary MR angiography(3D FISP,TR¡²msec¡³/TE¡²msec¡³=5.0/2.0, with 25¡Æflip
angle). In ten volunteers(single-dose injection group) pulmonary MR angiography was
performed after the adminstration of 0.1mmol/§¸(single dose injection group), while the
other ten(double-dose injection group) each received, prior to angiography, 0.2mmol/§¸.
In all cases, a timing examination was performed during axial turbo-FLASH
imaging(TR/TE/TI=8.5/4.0/100, 10¡Æflip angle) after injection of the same dose as that
used for subsequent contrast-enhanced pulmonary MR angiography. In both groups,
overall image quality, pulmonary artery visibility and contrast-to-noise ratio of the
pulmonary artery were assessed on the basis of images obtained.
Results : With regard to overall image quality, there was no significant statistical
difference between the two groups(P>0.05), and in both, depiction of the central and
lobar pulmonary artery was excellent. As regards depiction of the segmental artery, the
average grading of the single dose injection group was 2.83¡¾0.32, that of the double
dose injection group 2.85¡¾0.3, with no statistical significance(P>0.05). With respect to
contrast-to-noise ratio of the central, lobar, and segmental arteries, the best results
were obtained by the double dose injection group(P>0.05).
Conclusion : Although the contrast-to noise ratio in the double-dose injection group was
better than that in the single-dose group, differences in overall image quality and
pulmonary artery depiction were not statistically significant. Thus, single-dose,
contrast-enhanced 3-D ultrafast pulmonary MR angiography can provide useful images
in clinical trials.

Magnetic resonance imaging(MRI) three-dimensional; Pulmonary arteries MR; Magnetic resonance imaging(MRI) vascular studies;

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS